Your search for mepolizumab returned 118 results

Trial enrolled children from disadvantaged urban neighborhoods who have exacerbation-prone eosinophilic asthma

Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.

Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.

The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.

The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP.

For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously.

The researchers found that, compared with placebo, mepolizumab treatment correlated with significantly more accrued weeks of remission.

GlaxoSmithKline announced that the primary endpoint for its Phase 3 study of mepolizumab was met for the reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma.

Mepolizumab may be effective in patients with asthma that does not respond to omalizumab.